"Wet Macular Degeneration" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of RETINAL DEGENERATION in which abnormal CHOROIDAL NEOVASCULARIZATION occurs under the RETINA and MACULA LUTEA, causing bleeding and leaking of fluid. This leads to bulging and or lifting of the macula and the distortion or destruction of central vision.
| Descriptor ID |
D057135
|
| MeSH Number(s) |
C11.768.585.439.622
|
| Concept/Terms |
Wet Macular Degeneration- Wet Macular Degeneration
- Degeneration, Wet Macular
- Degenerations, Wet Macular
- Macular Degeneration, Wet
- Macular Degenerations, Wet
- Wet Macular Degenerations
|
Below are MeSH descriptors whose meaning is more general than "Wet Macular Degeneration".
Below are MeSH descriptors whose meaning is more specific than "Wet Macular Degeneration".
This graph shows the total number of publications written about "Wet Macular Degeneration" by people in this website by year, and whether "Wet Macular Degeneration" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 2 | 0 | 2 |
| 2014 | 3 | 0 | 3 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 3 | 0 | 3 |
| 2019 | 2 | 0 | 2 |
| 2020 | 5 | 0 | 5 |
| 2021 | 8 | 1 | 9 |
| 2022 | 4 | 0 | 4 |
| 2023 | 6 | 0 | 6 |
| 2024 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Wet Macular Degeneration" by people in Profiles.
-
MERLIN: Two-Year Results of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Ophthalmology. 2025 Feb; 132(2):131-140.
-
Impact of COVID-19 on a real-world treat-and-extend regimen with aflibercept for neovascular age-related macular degeneration. Can J Ophthalmol. 2025 Feb; 60(1):e92-e99.
-
Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study. Lancet. 2024 04 20; 403(10436):1563-1573.
-
Optimizing Visual Outcomes in Patients With Neovascular Age-Related Macular Degeneration: the Potential Value of Sustained Anti-VEGF Therapy. Ophthalmic Surg Lasers Imaging Retina. 2023 Nov; 54(11):654-659.
-
Safety of recent ophthalmic drugs and devices for wet macular degeneration. Curr Opin Ophthalmol. 2023 Sep 01; 34(5):363-368.
-
One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS? Registry. Ophthalmology. 2023 09; 130(9):937-946.
-
Factors Linked to Injection Interval Extension in Eyes with Wet Age-Related Macular Degeneration Switched to Brolucizumab. Ophthalmology. 2023 08; 130(8):795-803.
-
Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results. Ophthalmology. 2023 Jul; 130(7):735-747.
-
A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2023 06; 130(6):588-597.
-
Optical Coherence Tomography Biomarkers for Conversion to Exudative Neovascular Age-related Macular Degeneration. Am J Ophthalmol. 2023 03; 247:137-144.